Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14829MR)

This product GTTS-WQ14829MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14829MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5883MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ12688MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ5589MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ2677MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ274MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ2429MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ12685MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ14998MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW